Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

Clinical Biomarkers and World CDx Europe Summit

Clinical Biomarkers and World CDx Europe Summit


Date of beginning

Wednesday, 24 March 2021


2 days




Clinical Biomarkers and World CDx EU Team


This email address is being protected from spambots. You need JavaScript enabled to view it.


Clinical Biomarkers and World CDx Europe is uniting biomarker, diagnostic and precision medicine leaders to advance clinically predictive biomarkers to proven IVDs. Improving patient outcomes and standard of care, this meeting is built for biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver successful drug-Dx products. Following the FDA's approval of 12 personalised medicines and 7 diagnostics in 2019, then a record number of precision oncology drugs in H1 2020, demand is high for Dx-enabled therapies to reach the market. Despite the added pressures of the Covid-19 pandemic, in addition to a changing regulatory and fragmented environment, we are seeing significant progresses by pharma, academia and diagnostic expertise towards expediting the development of drugs in areas of great unmet medical need. It's now important key stakeholders come together to share successes and lessons learnt to contextualise on advances and collaborate to deliver therapeutic advances in a more time effective manner. Over the course of two days, the 11th annual Clinical Biomarkers and CDx Europe Summit will bring all stakeholders together to fast-track precision medicine through clinically validated biomarkers and companion diagnostics partnerships in Europe. The two-tracks meeting will tackle key conversations spanning biomarker discovery through to drug-Dx market penetration, enabling you with innovation to power pipeline progression. Join to hear and learn from true trailblazers on latest tools and techniques validating biomarker utility, overcoming patient selection challenges in rare disease, key clinical case-study learnings shaping diagnostic strategy in addition to the much needed core EU focus on navigating a tricky regulatory and reimbursement landscape to prevent incoming regulations hindering the delivery of critical drugs to patients in need. Featuring dynamic panels, 5+ hours of networking, interactive roundtables and not to mention the incredible 45+ expert speakers - You won't want to miss this important and timely opportunity to re-connect with your global precision medicine peers at this industry leading event! URLs:Brochure: Date and Time: On Wednesday March 24, 2021 at 1:00 pm (ends Thursday March 25, 2021 at 10:00 pm) Price:Free: USD 0.00 Speakers: Guillaume Desachy, Principal Biostatistician, AstraZeneca, Kristiina Rosin Regulatory Policy and Intelligence Manager Abbvie, Maria Orr Head of Precision Medicine Biopharmaceuticals AstraZeneca, Rob Hastings Precision Medicine Expert, Cardiovascular, Renal and Metabolism AstraZeneca, David Crosby Head of Prevention and Early Detection Research Cancer Research UK, Hugues Malonne Director General PostAuthorization Federal Agency for Medicines and Health Products, Jude O'Donnell Head, Regulatory Strategy Almac Diagnostic Services, Xavier Solé Acha Head of Unit of Bioinformatics for Precision Oncology Catalan Institute of Oncology, Ellie Corigliano Global Director Medical Affairs, Oncology, Thoracic and Pan Tumor Biomarkers and Diagnostics, Oncology Global Medical Affairs Merck and Co., James Duboff Strategic Partnerships Director Genomics England, John Armstrong Global Head of Discovery Galderma International, Marcia Weber Preclinical Manager Handl Therapeutics, Christophe Le Tourneau Senior Medical Oncologist, Head of the Department of Drug Development and Innovation (D3i) Institut Curie, Christopher Peters Clinical Senior Lecturer and Consultant Upper GI Surgeon Imperial College London, Patrick McGinley Head of Costing and SLR Maidstone and Tunbridge Wells NHS Trust, Thomas Kleen Chief Scientific Officer Immodulon Therapeutics, Caoimhe Vallely-Gilroy Head of Data Analytics and Strategy for Healthcare, Healthcare Digital and Data Merck KGaA, Clare Balendran Vice President, Translational Medicine Novo Nordisk, Jörg Engelbergs Scientific-Regulatory Expert Targeted and Personalized Biomedicines Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines (National Competent Authority responsible for Biomedicines), Alain Van Gool Head Translational Metabolic Laboratory, Department Laboratory Medicine Radboudumc, Gerard Sanderink, Global Head Biomarkers and Clinical Bioanalysis, Sanofi, Irene Bacalocostantis, Senior Manager, Combination Products and IVDs, Regulatory Affairs, Regeneron, Michael Schubert, Editor, The Pathologist Journal, Andreas Stange, Vice President, TÜV SÜD, Naim Alkhouri, Director, Fatty Liver Program, Vice President of Academic Affairs, Arizona Liver Health, Sibylle Hess, Senior Clinical Biomarker Expert, R and D, Translational Medicine and Early Development, Biomarkers and Clinical Bioanalyses (TMED-BCB), Sanofi, Vincent Mikol, Vincent Mikol, Sanofi, Andrew Biankin, Regius Professor of Surgery; Director, Wolfson Wohl Cancer Research Centre, University of Glasgow, Domenico Merante, Global Clinical Development TA Lead, Vifor Pharma, Julien Senac, Global Director, IVD Focus Team, TÜV SÜD, Rowena Sharp,e Director, Precision Medicine Trials, University of Birmingham, Will Green, Project Director, York Health Economics Consortium